Industry news

  • 26 May 2017

    Kazakhstan sets fixed prices for 105 medicinal products and medical devices

    GMP News

    The Memorandum became effective on May 23, 2017 and will be valid until the end of this year. The document was signed by the heads of leading pharmaceutical associations of Kazakhstan, including the Association for Support and Development of Pharmaceutical Activities of the Republic of Kazakhstan, Association of International Pharmaceutical Manufacturers in Kazakhstan, Association of Pharmaceutical Distributors of the Republic of Kazakhstan, Association PharmMedIndustry of Kazakhstan.

  • 26 May 2017

    Russia is establishing a competitive rehabilitation industry

    GMP News

    The Russian Ministry of Industry and Trade has prepared a draft Strategy for Developing the Manufacturing of Rehabilitation-Oriented Industrial Products until 2025.

  • 24 May 2017

    Syndax Prices Public Offering of Common Stock

    Syndax Prices Public Offering of Common Stock

    Syndax Pharmaceuticals, Inc. (Nasdaq:SNDX) announced today the pricing of an underwritten public offering of 3,750,000 shares of its common stock at a price to the public of $13.25 per share. The gross proceeds to Syndax from this offering, before deducting underwriting discounts and commissions and estimated offering expenses, are expected to be approximately $49.7 million. The offering is expected to close on May 31, 2017, subject to customary closing conditions.

  • 24 May 2017

    Russia's Pharmacy Chain sees online sales accounting for 10 percent of total by mid-2018

    Anna Pruchnicka and Anna Rzhevkina / Reuters

    Russian health and beauty products retailer Pharmacy Chain 36.6 expects online sales to account for 10 percent of total revenue by mid-2018 from just 1 percent now, its corporate finance director said.

  • 23 May 2017

    Syndax Announces Proposed Public Offering of Common Stock

    Syndax Announces Proposed Public Offering of Common Stock

    Syndax Pharmaceuticals, Inc. (Nasdaq:SNDX) announced today that it plans to offer and sell, subject to market and other conditions, $50 million of its common stock in an underwritten public offering. There can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering. Syndax also expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of shares sold in the public offering. All of the shares in the proposed offering are to be sold by Syndax.

  • 23 May 2017

    European Medicines Agency issued its 2016 annual report

    GMP News

    The European Medicines Agency (EMA) published 2016 annual report. It focuses on the Agency’s key achievements in the areas of medicine evaluation, support to research and development of new and innovative treatments and the safety monitoring of medicines in real life.

  • 23 May 2017

    Key growth drivers of Russian pharmaceutical retail run out of steam

    GMP News

    On the one hand, in Q1 2017, Russian pharmaceutical retail sector strengthened the positive trends of the past year. The demand for medicinal products is recovering, albeit slowly, both as a result of higher consumption in terms of physical volume and the shift of consumers to more expensive drugs. On the other hand, current positive trends are so far, alas, just a pleasant fact which, while making the retail pharmacies feel better in general, cannot serve, for a number of objective reasons, as a foundation for either quantitative or qualitative development of the industry.

  • 23 May 2017

    Drama and diagnosis on soap opera set troubles cancer doctors, puts Incyte in hot seat

    Beth Snyder Bulik / FiercePharmaMarketing

    Soap operas often include medical mysteries and miracles, but a couple of real-life doctors are concerned about Incyte's connection to the latest drama on General Hospital.

  • 22 May 2017

    Pharma Must Embrace Its Social Media Role

    Dawn Lacallade / Pharmaceutical Executive

    Social media permeates virtually every aspect of a person’s digital life. Patients are using social media as a major source of information and an integral part of their healthcare research journey. It is therefore imperative that pharma companies be present on social media to provide full and balanced information to consumers.

  • 19 May 2017

    Health Executives See Tech Firms Like Alphabet Remaking Industry

    bSonali Basak and Ed Hammond / Bloomberg

    Health-care executives expect counterparts at tech companies like Alphabet Inc., Google’s parent company, to transform their industry over three to five years, according to a Lazard Ltd. survey.

All Partners

All Portfolio

MEDIA CENTER

  • NovaMedica launched Technology Center to develop innovative drugs

    NovaMedica launched Technology Center to develop innovative drugs

    NovaMedica, a Russian pharmaceutical company (RUSNANO portfolio company), started operation of the Technology Center designed for the development and pilot production of innovative drug products. It comprises a complex of R&D laboratories and production areas with technological capabilities which are unique for the Russian pharmaceutical industry and one of the best in Europe. Crucial tasks of the Technology Center are to develop the advanced oral medical products of different pharmacotherapeutic groups, including those to treat cardiovascular and gastroenterological diseases, central nervous system diseases, and to create painkillers drugs of the new generation.  

All news